RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+21.23%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$631M
AUM Growth
+$631M
(+21%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
7.1%
Top 10 Holdings %
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.5M |
| 2 |
Glaukos
GKOS
|
$10.8M |
| 3 |
Esperion Therapeutics
ESPR
|
$9.48M |
| 4 |
Biogen
BIIB
|
$8.75M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$7.42M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$13.1M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$11.1M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$5.44M |
| 4 |
Centene
CNC
|
$4.45M |
| 5 |
Bristol-Myers Squibb
BMY
|
$4.35M |
Sector Composition
| 1 | Healthcare | 92% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.12% |
| 5 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
DexCom
DXCM
$30.9B
| $4.82M | 0.76% |
56,900
-27,900
| -33% | -$2.36M |
|
|
PTLA
52
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.73M | 0.75% |
120,805
| – | – |
|
|
ENDP
53
DELISTED
Endo International plc
ENDP
| $4.49M | 0.71% |
402,303
+102,103
| +34% | +$1.14M |
|
|
RVNC
54
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.37M | 0.69% |
210,000
| – | – |
|
55
Universal Health Services
UHS
$11.6B
| $4.36M | 0.69% |
35,000
+5,000
| +17% | +$622K |
|
56
Rigel Pharmaceuticals
RIGL
$710M
| $4.24M | 0.67% |
1,282,000
| – | – |
|
|
NXTM
57
DELISTED
NxStage Medical Inc.
NXTM
| $4.13M | 0.65% |
153,901
-5,000
| -3% | -$134K |
|
58
Omnicell
OMCL
$1.51B
| $4.01M | 0.63% |
98,537
-20,000
| -17% | -$813K |
|
|
AERI
59
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.86M | 0.61% |
85,000
+50,000
| +143% | +$2.27M |
|
60
FibroGen
FGEN
$48.4M
| $3.81M | 0.6% |
154,341
+50,341
| +48% | +$1.24M |
|
61
DaVita
DVA
$9.72B
| $3.74M | 0.59% |
55,000
+10,000
| +22% | +$680K |
|
|
WBA
62
DELISTED
Walgreens Boots Alliance
WBA
| $3.74M | 0.59% |
45,000
+20,000
| +80% | +$1.66M |
|
63
Neurocrine Biosciences
NBIX
$13.5B
| $3.68M | 0.58% |
85,000
+45,000
| +113% | +$1.95M |
|
64
Viatris
VTRS
$12.3B
| $3.51M | 0.56% |
90,000
+80,000
| +800% | +$3.12M |
|
|
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.39M | 0.54% |
30,000
+10,000
| +50% | +$1.13M |
|
66
MacroGenics
MGNX
$121M
| $3.26M | 0.52% |
175,000
+20,000
| +13% | +$372K |
|
|
ARRY
67
DELISTED
Array Biopharma Inc
ARRY
| $3.13M | 0.5% |
350,000
-200,000
| -36% | -$1.79M |
|
|
IMMU
68
DELISTED
Immunomedics Inc
IMMU
| $3.1M | 0.49% |
+479,610
| New | +$3.1M |
|
69
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.09M | 0.49% |
90,000
+20,000
| +29% | +$688K |
|
70
Labcorp
LH
$22.8B
| $3.09M | 0.49% |
21,550
-8,450
| -28% | -$1.21M |
|
71
Intuitive Surgical
ISRG
$158B
| $3.07M | 0.49% |
+4,000
| New | +$3.07M |
|
|
RDUS
72
DELISTED
Radius Health, Inc.
RDUS
| $2.9M | 0.46% |
75,000
+20,000
| +36% | +$773K |
|
|
TTPH
73
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $2.76M | 0.44% |
300,000
| – | – |
|
|
ADMS
74
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.71M | 0.43% |
155,000
+25,000
| +19% | +$438K |
|
|
KERX
75
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $2.62M | 0.41% |
425,111
| – | – |
|